An Angry Bed Partner

Applebee, Garrick; Attarian, Hrayr; Schenck, Carlos H.

doi:10.5664/jcsm.27606

Cited by 15 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been estimated that the odds ratio of developing RBD is 1.9 with antidepressant use [ 27 ], particularly with selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). A few case reports have shown improvement of RBD upon discontinuation of fluoxetine [ 28 , 29 ], but RBD can persist for at least 19 months after discontinuation of SSRI medications [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Comorbid neuropsychiatric and autonomic features in REM sleep behavior disorder

Barone

Wang

Ravdin

et al. 2020

Clinical Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Objective Our aim is to define the extent of comorbidities in order to improve clinical care of patients with idiopathic rapid eye movement sleep behavior disorder (iRBD) utilizing the REM Sleep Behavior Disorder Associations with Parkinson's Disease Study (RAPiDS) cohort. Methods Consecutive adult study participants with iRBD confirmed on polysomnogram (PSG) were prospectively recruited from the Weill Cornell Center for Sleep Medicine. Evaluations comprised multiple facets of sleep, neurological, autonomic, and psychiatric function. Results Participants evaluated included 30 individuals with iRBD, with mean 1.5 ± 2.3 years from PSG to neuropsychiatric evaluation. Mean age was 59.5 ± 16.0 years at time of PSG, and 6/30 were women. Urinary difficulties were reported in 14/30 (47%): slight 7 (23%), mild 4 (13%), moderate 2 (7%), and severe 1 (3.0%). Ten out of 29 (34%) had abnormal Montreal Cognitive Assessment (MoCA) scores and the mean was 26.5 ± 3.2. The distribution of MoCA scores was significantly associated with urinary problems insofar as the more severe urinary problems were, the lower the MoCA scores (p = 0.04). Conclusions In this RAPiDS cohort, we detected an unexpectedly high occurrence of non-motor dysfunction. Our results point to the need for screening patients with iRBD for complaints that are actionable, for example those affecting mood, cognition, urinary function, and bowel function. We propose the term RBD+ to be used to identify such individuals. For the quality of life in patients diagnosed with RBD, a closer look by the clinician should be enacted, with appropriate referrals and workup.

show abstract

Section: Discussionmentioning

confidence: 99%

Comorbid neuropsychiatric and autonomic features in REM sleep behavior disorder

Barone

Wang

Ravdin

et al. 2020

Clinical Parkinsonism & Related Disorders

View full text Add to dashboard Cite

show abstract

“…There were also two unique features in this case. First, the latency to drug induced RBD was longer than the interval, usually less than 6 months, previously reported for SSRI induced RBD [ 10 , 14 ]. Actually, in our case, excessive EMG activity during REM sleep was found during the first PSG assessment taken when the patient had been taking duloxetine for 7 months, but without typical RBD symptoms.…”

Section: Discussionmentioning

confidence: 86%

“…In parallel, RSWA sharply decreased then almost completely disappeared after discontinuation of duloxetine for 9 and 37 days, respectively. Previous studies demonstrated that RBD symptoms remained after discontinuing fluoxetine for 6 weeks or even 27 months [ 14 , 15 ]. Similarly, RSWA persisted for a long time even though the abnormal behaviors had disappeared [ 16 , 17 ].…”

Section: Discussionmentioning

confidence: 99%

Duloxetine-induced rapid eye movement sleep behavior disorder: a case report

et al. 2017

View full text Add to dashboard Cite

BackgroundTricyclic antidepressants and selective serotonin reuptake inhibitors have been reported to induce the symptoms of rapid eye movement (REM) sleep behavior disorder (RBD) or to exacerbate REM sleep without atonia. With this case report, we found an association between typical RBD and duloxetine, a serotonin-noradrenaline reuptake inhibitor.Case presentationWe present a case of a 62-year-old woman who experienced enactment behaviors with violent dreams that were associated with increased tonic or phasic chin electromyography activity during REM sleep after treated with duloxetine. RBD symptoms were gradually reduced and completely ceased after discontinuation of duloxetine for 37 days.ConclusionThe current case appears to be the first observation of duloxetine-induced RBD. We describe features of RBD induced by duloxetine that are similar and different from that induced by tricyclic antidepressants and selective serotonin reuptake inhibitors.

show abstract

“…When such intensification occurs in a negative context, it is nonetheless associated with improvements in symptoms of depression (60). Fluoxetine has also been incriminated in provoking episodes of RBD (61).…”

Section: Selective Serotonin Reuptake Inhibitor Antidepressantsmentioning

confidence: 99%

Dreams, Sleep, and Psychotropic Drugs

Nicolas

Ruby

2020

Front. Neurol.

View full text Add to dashboard Cite

Over the past 60 years, the impact of psychotropic drugs on dream recall and content has been scarcely explored. A review of the few existing experimental results on the topic leads us to the following conclusions. For antidepressant drugs, in the great majority, they reduce dream recall frequency (DRF), and the improvement of depressive symptoms is associated with an increase of positive emotion in dream content. For sedative psychotropic drugs, their improvement of sleep quality is associated with a reduction of DRF, but the effect on dream content is less clear. Few occurrences of nightmare frequency increase have been reported, with intake of molecules disturbing sleep or with the withdrawal of some psychotropic drugs. Importantly, the impact of psychotropic drugs on rapid eye movement (REM) sleep does not explain DRF modulations. The reduction of intra-sleep awakenings seems to be the parameter explaining best the modulation of DRF by psychotropic drugs. Indeed, molecules that improve sleep continuity by reducing intra-sleep awakenings also reduce the frequency of dream recall, which is coherent with the "arousal-retrieval model" stating that nighttime awakenings enable dreams to be encoded into long-term memory and therefore facilitate dream recall. DRF is nonetheless influenced by several other factors (e.g., interest in dreams, the method of awakening, and personality traits), which may explain a large part of the variability of results observed and cited in this article.

show abstract

An Angry Bed Partner

Abstract: Figure 1-30-second epoch tracing of polysomnography recorded during REM sleep reveals persistent chin EMG tone during REM sleep, with overt whole-body movements at the end of the epoch.

Cited by 15 publications

References 0 publications

Comorbid neuropsychiatric and autonomic features in REM sleep behavior disorder

Comorbid neuropsychiatric and autonomic features in REM sleep behavior disorder

Duloxetine-induced rapid eye movement sleep behavior disorder: a case report

Dreams, Sleep, and Psychotropic Drugs

Contact Info

Product

Resources

About